Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?

Antonio Ruggiero, Palma Maurizi, Stefano Mastrangelo, Ilaria Lazzareschi, Cesare Colosimo, Mario Balducci, Daniela Rizzo, Maria Scalzone, Giorgio Attina', Vita Ridola, Massimo Caldarelli, Riccardo Riccardi

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

19 Citazioni (Scopus)

Abstract

Background: The purpose of this study was to assess the efficacy and toxicity of radiotherapy (RT) with concurrent temozolomide (TMZ) chemotherapy followed by adjuvant TMZ in children with diffuse intrinsic pontine glioma (DIPG). Methods: Patients younger than 18 years with newly diagnosed DIPG were enrolled. Children were treated with focal RT along with concurrent daily TMZ. Four weeks after completing the initial RT-TMZ schedule, adjuvant TMZ was given every 28 days up to 12 cycles or progression disease. Results: Fifteen children with a median age of 9 years were enrolled. Fourteenth out of the 15 patients completed the chemoradiotherapy. The toxicity associated with TMZ was primarily haematopoietic. At a median follow-up of 15 months 13 children had died and 2 children were alive with progressive disease. No patient experienced complete response (CR). The median time to progression was 7·15 months. Conclusion: Chemoradiotherapy with TMZ followed by adjuvant TMZ did not improve the poor prognosis associated with DIPG in children.
Lingua originaleEnglish
pagine (da-a)106-110
Numero di pagine5
RivistaJournal of Chemotherapy
Volume27
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • Children,
  • Diffuse intrinsic pontine glioma
  • Temozolomide,

Fingerprint Entra nei temi di ricerca di 'Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?'. Insieme formano una fingerprint unica.

Cita questo